PDCD1 and Miyoshi myopathy: A retrospective study (20) including 35 patients with advanced MM treated with anti-PD-1 produced comparable results of 23% (95% CI: 10–40%) of overall responds rate(ORR), PFS of 3.9 months, and a median overall survival of 12.4 months.